Evoke Pharma Q2 EPS $(0.93) Misses $(0.06) Estimate, Sales $2.55M Miss $2.98M Estimate
Portfolio Pulse from Benzinga Newsdesk
Evoke Pharma (NASDAQ:EVOK) reported Q2 earnings per share (EPS) of $(0.93), significantly missing the analyst estimate of $(0.06). The company also reported quarterly sales of $2.55 million, which fell short of the $2.98 million estimate. Despite the misses, sales increased by 125.58% year-over-year.
August 13, 2024 | 12:23 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Evoke Pharma reported a significant miss in Q2 EPS and sales compared to analyst estimates. The EPS miss was 1450% and the sales miss was 14.38%. Despite these misses, sales increased by 125.58% year-over-year.
The significant miss in both EPS and sales compared to analyst estimates is likely to negatively impact the stock price in the short term. However, the substantial year-over-year sales growth may provide some support.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100